

Section 2C: Quality Improvement Measures

STANDARD – QI Measures

- 2.1C Facilities are required to have a process in place to evaluate the QI measures outlined in sections 2.1.1C through 2.1.4C.

(See Guidelines below for further recommendations.)

- 2.1.1C Radiopharmaceutical Therapy Appropriateness –The facility must evaluate the appropriateness of the therapy performed and categorized as:
- 2.1.1.1C indicated; and
 - 2.1.1.2C contraindicated
- 2.1.2C Quality and Safety Review of the Radiopharmaceutical Therapy Administration –To assess and improve the safety of therapy procedures being performed. The review must include, but is not limited to the evaluation of:
- 2.1.2.1C correct patient preparation, as specified in the clinical written procedures, at the time of study (labs, etc.);
 - 2.1.2.2C verification of written directive completeness and compliance;
 - 2.1.2.3C adherence to facility radiopharmaceutical therapy protocols;
 - 2.1.2.4C verification of appropriate post therapy care.
- 2.1.3C Final Report and Documentation Completeness and Timeliness – The facility must evaluate the final report for completeness and timeliness as required in the Standards.

Section 2C: Quality Improvement Measures *Guidelines*

- 2.1C *Administrative Quality* – To assess and improve the administrative quality of the facility's operation. Areas that may be assessed include, but are not limited to: scheduling back logs; patient wait times; accuracy of patient information during scheduling; completeness of documentation; time from completion of procedure to distribution of final report; patient satisfaction; referring physician satisfaction